ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "ANCA associated vasculitis"

  • Abstract Number: 0724 • ACR Convergence 2024

    Incidence of ANCA-Associated Vasculitis in a Northern Spanish Health Region Between 2000-2023: A Populatio-based Study

    Fabricio Benavides1, Alba Herrero-Morant2, Salma Al Fazazi3, Vanesa Calvo-Rio4, Mónica Renuncio-García5, Adrián Martín-Gutiérrez6, Amparo Sánchez-López7, Claudia Poo-fernandez7, Clara Escagedo-Cagigas7, Maria Rodríguez-Vidriales1 and Ricardo Blanco-Alonso8, 1Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, 2Hospital Universitario Marqués de Valdecilla, Ontinyent, Cantabria, Spain, 3Hospital Universitario Virgen de la Victoria, Málaga, Andalucia, Spain, 4Valdecilla Hospital, Santander, Cantabria, Spain, 5Division of Immunology, Hospital Universitario Marqués de Valdecilla, Immunopathology Group, IDIVAL, Santander, Spain, 6Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, 7Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, 8Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCA) associated vasculitis (AAV) is a group of vasculitis that affect small vessels. Includes Granulomatosis with polyangiitis (GPA), Eosinophilic granulomatosis with…
  • Abstract Number: 1254 • ACR Convergence 2024

    The Impact of Eosinophilic Granulomatosis with Polyangiitis on the Health-Related Quality of Life of Patients and Their Ability to Work: Evidence from a Real-World Survey in Clinical Practice

    Robert Spiera1, Paul Dolin2, Anat Shavit2, Jennifer Rowell3, Chris Edmonds4, Josefine Persson5, Danuta Kielar6, Daniel Mascia7, James Siddall7, Tia Pennant7, Fritha Hennessy7 and Stephanie Y. Chen8, 1Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, 2BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, 3Market Access and Pricing, AstraZeneca, Cambridge, England, United Kingdom, 4Market Access and Pricing, AstraZeneca, Gaithersburg, MD, 5Market Access and Pricing, AstraZeneca, Gothenburg, Sweden, 6Biopharmaceuticals Medicine, AstraZeneca, Cambridge, United Kingdom, 7Adelphi Real World, Bollington, United Kingdom, 8BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare anti-neutrophil cytoplasmic antibody-associated vasculitis that confers significant disease burden. This real-world study described the impact of…
  • Abstract Number: 1607 • ACR Convergence 2024

    Low Concentrations of Anti-C5a Complement Receptor Antibodies Are Associated with Relapse in Eosinophilic Granulomatosis with Polyangiitis (EGPA)

    Sebastian Klapa1, Sabrina Arnold2, Antje Müller2, Andreas Koch3, Anja Staehle4, Wataru Kähler3, Harry Heidecke5, Gabriela Riemekasten2 and Peter Lamprecht2, 1University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, 2University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, Germany, 3Christian-Albrechts-University Kiel, Institute of Experimental Medicine, Kiel, Germany, 4University of Lübeck, Department of Rheumatology and Immunology, Lübeck, Germany, 5CellTrend GmbH, Luckenwalde, Germany

    Background/Purpose: Complement activation has been shown to play an important role in the pathogenesis of the two major anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) variants,…
  • Abstract Number: 2481 • ACR Convergence 2024

    General, Nervous System, Eye, and Skin Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis

    Rula A. Hajj-Ali1, Duvuru Geetha2, Raashid Luqmani3, Christian Pagnoux4, Darcy Trimpe5, David Jayne6 and Peter Merkel7, and ADVOCATE Study Group, 1Cleveland Clinic, Cleveland, OH, 2Johns Hopkins University, Baltimore, MD, 3University of Oxford, Abingdon, United Kingdom, 4Mount Sinai Hospital, Toronto, ON, Canada, 5Amgen Inc., Thousand Oaks, CA, 6University of Cambridge, Cambridge, United Kingdom, 7University of Pennsylvania, Philadelphia, PA

    Background/Purpose: The most common types of ANCA-associated vasculitis, granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), can affect a range of organs, including the kidneys,…
  • Abstract Number: 2651 • ACR Convergence 2024

    Vasculitis Associated with VEXAS Syndrome

    Megan Sullivan1, Kambiz Kalantari2, Carolyn Mead-Harvey3, Yael Kusne4, Mrinal Patnaik2, Abhishek Mangaonkar2, Ronald Go2, Daniel Montes2, Kaaren Reichard2, Horatiu Olteanu2, Melanie Bois2, Alexander Hines2, Julio Sartori-Valinotti5, Kenneth Warrington2 and Matthew Koster2, 1Mayo Clinic Arizona, Scottsdale, AZ, 2Mayo Clinic, Rochester, MN, 3Mayo Clinic, Scottsdale, AZ, 4Mayo Clinic, Phoenix, AZ, 5Mayo Clinic, Rohester, MN

    Background/Purpose: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a recently defined clinical entity that causes hematologic and autoinflammatory symptoms. Since its initial description…
  • Abstract Number: 0725 • ACR Convergence 2024

    Serum Glial Fibrillary Acidic Protein Could Assess Cross-sectional Vasculitis Activity by Reflecting Renal Involvement in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis

    Lucy Eunju Lee1, Taejun Yoon2, Yong-Beom Park2 and Sang-Won Lee2, 1Yonsei University, Seoul, South Korea, 2Yonsei University College of Medicine, Seoul, Republic of Korea

    Background/Purpose: Glial fibrillary acidic protein (GFAP), an intermediate filament protein produced by astrocytes in the CNS, has been identified as a biomarker for disease activity…
  • Abstract Number: 1276 • ACR Convergence 2024

    Therapeutic Drug Monitoring (TDM) of Rituximab to Predict Early B-Cell Repopulation in Children

    Rana Alsulami1, Bindiya Chugani2, Joley Johnstone2, Ann Yeh2, Floris Loeff3, Linda Hiraki2, Andrea Knight4, Deborah Levy2 and Ruud Verstegen2, 1University of Toronto, Toronto, ON, Canada, 2The Hospital for Sick Children, Toronto, ON, Canada, 3Sanquin Diagnostic Services, Amsterdam, Netherlands, 4Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Rituximab is increasingly used in pediatric inflammatory diseases, with dosing extrapolated from adult data due to a lack of pediatric-specific pharmacokinetic (PK) information. Children…
  • Abstract Number: 1608 • ACR Convergence 2024

    Interstitial Lung Disease in ANCA-associated Vasculitis: A Retrospective Study of Clinical Characteristics, Radiographic Features, and Outcomes

    Janelle Castellino1, Matas Orentas2, Joshua Moran3, Joshlean Fair1, Yanyu Zhang4 and Aleksandra Bukiej5, 1Rush University Medical Center, Chicago, IL, 2RUMC, Chicago, IL, 3Rush University Medical Center - IM Residency, Chicago, IL, 4Rush University Medical Center, Chicago, 5Rush University Medical Center, River Forest, IL

    Background/Purpose: Interstitial lung disease (ILD) is a significant manifestation of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and…
  • Abstract Number: 2483 • ACR Convergence 2024

    Efficacy and Safety of Avacopan over 12 Months in Japanese Patients with MPA/GPA: A Single-center Study

    Yusuke Ushio1, Hiromi Shimada2, taichi miyagi3, Koichi Sugihara4, Mao Mizusaki5, Rina Mino5, Hayamasa yamaguchi5, Naoto Manabe5, Shusaku Nakashima2 and Hiroaki Dobashi2, 1Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki, Kita District, Kagawa, Japan, 2Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, 3Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, kidagun, Japan, 4Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Kagawa Prefecture, Japan, 5Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan

    Background/Purpose: Avacopan, an oral C5a receptor inhibitor, was demonstrated to be an alternative to glucocorticoids (GC) in the treatment of microscopic polyangiitis (MPA)/granulomatosis with polyangiitis…
  • Abstract Number: 2689 • ACR Convergence 2024

    Characterization of Alpha-1 Antitrypsin Function in ANCA-Associated Vasculitis

    Lynn Fussner1, Ivan Bilic2, Carol McAlear3, David Cuthbertson4, Jie Cheng5, Elise Chen5, Markus Weiller2, Ulrich Specks6 and Peter Merkel3, and for the Vasculitis Clinical Research Consortium, 1The Ohio State University, Columbus, OH, 2Takeda Pharmaceuticals, Vienna, Austria, 3University of Pennsylvania, Philadelphia, PA, 4University of South Florida, Tampa, FL, 5Takeda Pharmaceuticals, Cambridge, MA, 6Mayo Clinic, Rochester, MN

    Background/Purpose: Two separate genome-wide association studies demonstrated that polymorphisms in SERPINA1, encoding serine protease inhibitor alpha-1 antitrypsin (A1AT), are associated with increased risk of developing…
  • Abstract Number: 0726 • ACR Convergence 2024

    Management of ANCA Vasculitis-Associated Orbital Inflammatory Disease: A Systematic Literature Review

    Emma Neary1, Katie Healey2, Marie Clements-Baker3, Jean-Paul Makhzoum4 and Arielle Mendel5, 1McGill University, Montreal, QC, Canada, 2Memorial University of Newfoundland, St. John's, NL, Canada, 3Queen's University, Kingston, ON, Canada, 4Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, 5McGill University Health Centre, Montreal, QC, Canada

    Background/Purpose: Ocular manifestations are common in ANCA-associated vasculitides (AAV), with orbital inflammatory disease (OID) representing a significant subset. Despite being a vision-threatening complication, OID remains…
  • Abstract Number: 1294 • ACR Convergence 2024

    Using Case-Based Continuing Education to Identify and Address Knowledge and Behavior Gaps in ANCA-associated Vasculitis

    Bharati Hegde, Jillian Scavone, Katie Robinson and Robert Esgro, Vindico Medical Education, West Deptford, NJ

    Background/Purpose: Given the rarity and non-specific symptoms associated with ANCA-associated vasculitis (AAV), rheumatology clinicians are challenged to use best practices for patient recognition and management,…
  • Abstract Number: 1609 • ACR Convergence 2024

    Characteristics of a Cohort of Patients with Interstitial Lung Disease and ANCA Positivity in a University Hospital

    Cristina Valero1, Claudia Valenzuela2, Elisa Martínez-Besteiro3, Patricia Quiroga Colina4, Arantzazu Alfranca5, Esther Vicente-rabaneda6, Santos Castañeda6 and Rosario García-Vicuña7, 1Hospital de la Princesa, Madrid, Spain, 2ILD Unit, Pulmonology Department, Hospital Universitario de la Princesa, University Autonomade Madrid, Madrid, Spain, Madrid, Madrid, Spain, 3Pulmonology Service, Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Spain, Madrid, Madrid, Spain, 4Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, 5Immunology Service, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, Madrid, Madrid, Spain, 6Hospital Universitario de La Princesa, Madrid, Spain, 7Hospital Universitario de la Princesa, Madrid, Madrid, Spain

    Background/Purpose: The prevalence of ANCA positivity at diagnosis of interstitial lung disease (ILD) ranges between 4-36% for anti-MPO and 2-4% for anti-PR3. ILD is more…
  • Abstract Number: 2484 • ACR Convergence 2024

    Real-World Use of Avacopan for ANCA-Associated Vasculitis Beyond 52 Weeks

    Julia Ford1, Abdallah Geara2, Duvuru Geetha3 and Ora Singer4, 1University of Michigan, Ann Arbor, MI, 2University of Pennsylvania, Philadelphia, PA, 3Johns Hopkins University, Baltimore, MD, 4University of Michigan, Huntington Woods, MI

    Background/Purpose: The landmark ADVOCATE trial, which led to the approval of avacopan (AVP) as adjunctive treatment of ANCA-associated vasculitis (AAV), treated patients with AVP for…
  • Abstract Number: 2690 • ACR Convergence 2024

    ANCA IgG Promotion of Neutrophil Recruitment, Migration and Vascular Damage in ANCA Associated Vasculitis May Be Enhanced by Hypoxia

    Noelle Pisacano, Amrita Dhutia, Stephen Rothery, Charles Pusey, Edwin Chilvers, Andrew Cowburn, Katharine Lodge and Maria Prendecki, Imperial College London, London, United Kingdom

    Background/Purpose: Neutrophils are main mediators of disease in ANCA associated vasculitis (AAV). Pathogenic ANCA IgG on neutrophils promotes neutrophil adhesion and migration at the endothelium.…
  • 1
  • 2
  • 3
  • …
  • 19
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology